Year

Category

Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD

April 16, 2024

Tris Digital Health enters into licensing agreement with Braingaze to develop and commercialize first-in-class, AI-enhanced technology that offers healthcare professionals an objective tool to improve accuracy of ADHD diagnosis.

Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance

February 07, 2024

– Michael brings more than two decades of experience at global pharmaceutical, biotechnology and medical device companies – MONMOUTH JUNCTION, NJ, February 7, 2024 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced…

Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel

January 22, 2024

— Franchesca brings more than a decade of experience leading legal functions at pharmaceutical and life science companies – MONMOUTH JUNCTION, NJ, [January 22, 2024] – BusinessWire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced…

Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder

October 30, 2023

— National direct-to-patient program allows patients and caregivers to obtain DYANAVEL XR extended-release tablet prescriptions from digital pharmacy — MONMOUTH JUNCTION, NJ, October 30, 2023 – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced…

Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder

September 25, 2023

– Potential to address unmet need for millions of Canadian children and their parents with fast-acting, long-lasting liquid and chewable tablet – MONMOUTH JUNCTION, NJ, September 25, 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced…

Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

September 05, 2023

– Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids – – Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023…

Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH’s National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder

August 28, 2023

– Funding will support preclinical through Phase 2 studies, with preclinical research expected to initiate in Q4 2023 –  MONMOUTH JUNCTION, NJ, August 28, 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced that…

Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline

May 02, 2023

  – Thomas Englese, a 20+ year industry veteran with a track record of success at leading biopharmaceutical companies, joins as chief commercial officer – – Marc Lesnick, Ph.D., appointed as chief development officer, bringing more than 20 years of experience in multiple therapeutic areas…

Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone

December 13, 2022

— Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids —…

Tris Pharma Announces Acquisition of New, Late-Stage Drug Candidate for Pain

December 07, 2022

Non-opioid, novel mechanism of action for pain, highly differentiated safety profile. Potential to address significant unmet needs in acute and chronic pain. MONMOUTH JUNCTION, NJ, December 7, 2022 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a fully integrated, innovation-driven CNS company with a robust portfolio of FDA-approved products for the…

Tris Pharma and Pediatrix Therapeutics Announce Expansion of Partnership to Commercialize Tris’s ADHD Portfolio and Pipeline Products in China

December 01, 2022

MONMOUTH JUNCTION, NJ, December 1, 2022/ PRNewswire/ – Tris Pharma, Inc. (“Tris”),a fully integrated, innovation-driven CNS company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), and a pipeline of treatments for pain, addiction, spasticity and narcolepsy, and Pediatrix Therapeutics (“Pediatrix”dafabet live dealer game), a pediatrics-focused company…

Tris Pharma Announces Continued Supply and Availability of DYANAVEL® XR (amphetamine) Tablets and Oral Suspension for ADHD Despite Adderall shortage

October 19, 2022

Once daily extended release provides early onset and full day coverage MONMOUTH JUNCTION, NJ, October 19, 2022 PRNewswire/ – Tris Pharma, Inc. (Tris) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII…

Tris Pharma Announces US District Court Upholds Validity of QuilliChew ER® Patents; Rules Teva Infringes Tris Patents

August 18, 2022

MONMOUTH JUNCTION, NJ, August 18, 2022/ PRNewswire/ – Tris Pharma, Inc. (“Tris”) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today the decision by the US District Court for the District of New Jersey to uphold the validity of various patents relating to QuilliChew ER®…

Tris Pharma Announces Availability of New DYANAVEL® XR (amphetamine) Tablets for ADHD

August 16, 2022

Once daily extended release provides early onset and full day coverage MONMOUTH JUNCTION, NJ, August 16, 2022/ PRNewswire/ – Tris Pharma, Inc. (Tris) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII are now…

Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation

July 27, 2022

First oxybate product to provide both once a night dosing and very low sodium Novel formulation developed using Tris’s proprietary RaftWorksTM and LiquiXR® Technology MONMOUTH JUNCTION, July 27, 2022 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today…

Tris Pharma Announces Publication of Study Results Highlighting the Efficacy and Safety of DYANAVEL® XR (amphetamine) Tablets for the Treatment of the Symptoms of ADHD in Adults

July 22, 2022

Tris announces the publication of a Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of DYANAVEL XR Tablets in Adults with ADHD in the Journal of Clinical Psychiatry. The article can be found here. The study demonstrated that DYANAVEL XR tablets are an effective and well-tolerated treatment for the symptoms of ADHD in…

Tris Pharma announces U.S. Court of Appeals for the Federal Circuit Affirms Validity of Quillivant XR® Patents; Rules Teva Infringes Tris Patents

July 20, 2022

MONMOUTH JUNCTION, July 20, 2022 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision on July 7, 2022 upholding the validity and infringement of various…

Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD

November 05, 2021

In a clinical study in adults, DYANAVEL XR tablets demonstrated bioequivalence to DYANAVEL XR (amphetamine) extended-release oral suspension. ADHD patients taking Dyanavel XR oral suspension can conveniently switch to the same dose of DYANAVEL XR Tablets. With multiple dosage strengths, including one functionally-scored, DYANAVEL XR extended-release tablets offer several dosing…

Tris Pharma® Hires Seasoned Business Development Executive Anthony Amato joins as Executive Vice President Business Development – Generics Division

October 07, 2021

MONMOUTH JUNCTION, NJ, October 7, 2021 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related conditions, today announced that Anthony Amato has joined…

Tris Pharma® Announces Acquisition of Park Therapeutics – Pain Company with First-in-class, Phase III-Ready New Chemical Entity (NCE)

April 29, 2021

Novel mechanism of action, highly differentiated safety profile, 2000+ subjects studied in 27 clinical trials across Europe and US; FDA Fast Track status granted NCE has potential to addresses significantly under-served market comprising acute and chronic pain, central and peripheral neuropathy, cancer pain, and addiction treatment MONMOUTH JUNCTION, NJ, April…

Tris Pharma and Athena Bioscience Announce Exclusive License Agreement to Commercialize Near-to-Market Long-Acting Antihypertensive Product in the U.S.

February 22, 2021

MONMOUTH JUNCTION, NJ and ATHENS, GA, February 22, 2021/ PRNewswire/ – Tris Pharma, Inc. (“Tris”) and Athena Bioscience LLC (“Athena”) announced today that they have entered into an agreement by which Athena received exclusive rights to commercialize a long-acting antihypertensive product developed using  Tris’ proprietary technology. On average, only 50%…

APSARD and Tris Pharma Announce the 2021 Tris Research Award in ADHD

January 28, 2021

MONMOUTH JUNCTION, NJ, January 28, 2021 / PRNewswire/ – The American Professional Society of ADHD and Related Disorders (“APSARD”), a professional organization focused on improving outcomes for individuals with ADHD and their families, and Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products for…

Tris Pharma Presents Positive Results from Phase 3 Study of Amphetamine Extended-Release Tablet in Adults with ADHD

January 20, 2021

Study met primary endpoint measure of sustained attention in adults with ADHD Showed statistically significant improvement vs. placebo in mean PERMP-Total score measured from 0.5 hours to 14 hours post-dose  No new adverse reactions reported during the study MONMOUTH JUNCTION, NJ, January 20, 2021 / PRNewswire/ – Tris Pharma, Inc.

Tris Pharma to Debut Amphetamine Extended-Release Tablet Efficacy and Safety Data at the 2021 APSARD Annual Meeting

January 15, 2021

MONMOUTH JUNCTION, NJ, January 15, 2021 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that it will present pivotal…

Tris Pharma Hires Seasoned Research & Development Executive

December 18, 2020

Alfred Liang to join as Vice President, Research & Development MONMOUTH JUNCTION, NJ, December 18, 2020 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder…

Tris Pharma and Neuraxpharm Group Announce Partnership to Commercialize Tris’ Quillivant XR and Quillichew ER in Europe

December 08, 2020

MONMOUTH JUNCTION, NJ, DÜSSELDORF, GERMANY and BARCELONA, SPAIN, December 8, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company…

Tris announces US District Court Upholds Validity of Quillivant XR® Patents; Rules Teva Infringes Tris Patents

December 01, 2020

MONMOUTH JUNCTION, December 1, 2020 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, announced the decision by the US District Court for the District of Delaware to uphold…

Tris Pharma and Medison Pharma Announce Exclusive License Agreement to Commercialize Tris’ Quillivant XR in Israel

November 17, 2020

MONMOUTH JUNCTION, NJ and PETACH TIKVA, ISRAEL, November 17, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Medison Pharma (“Medison”), a leading international commercial partner for…

Tris Pharma Launches New ADHD Portfolio Website for Patients and Caregivers

November 10, 2020

MONMOUTH JUNCTION, NJ, November 10, 2020 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, today announced the launch of…

Tris Pharma to Present Amphetamine Extended-Release Tablet Data at the Research Pipeline Session of 2020 American Academy of Child and Adolescent Psychiatry Meeting

October 22, 2020

MONMOUTH JUNCTION, NJ, October 22,  2020 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that Amy Everitt, MS, PharmD…

Tris Pharma Launches its Scientific Advisory Board

October 06, 2020

MONMOUTH JUNCTION, NJ, October 6, 2020/PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, successfully convened the inaugural meeting of its Scientific…

Tris Pharma Launches Redesigned Website for ADHD Healthcare Professionals

September 17, 2020

MONMOUTH JUNCTION, NJ, September 17, 2020 / PRNewswire/ – Tris Pharma, Inc. (Tris), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, announced today the launch of a redesigned website for healthcare professionals (HCPs).  This newly…

Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada

July 09, 2020

MONMOUTH JUNCTION, NJ and MISSISSAUGA, ONTARIO, CANADA, July 9, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga,…

Tris Pharma Launches New Corporate Website

June 25, 2020

MONMOUTH JUNCTION, NJ, June 25, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, today announced dafabet live casinothe launch of a new…

Quillivant XR®, QuilliChew ER® and Dyanavel® XR are 100% Made in the U.S.A. and Remain Consistently Supplied During COVID-19 Pandemic

March 17, 2020

MONMOUTH JUNCTION, NJ, March 17, 2020 / PRNewswire/ - Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved...

APSARD and Tris Pharma Announce the Inaugural Tris Research Award in ADHD

January 17, 2020

MONMOUTH JUNCTION, NJ, January 17, 2020 / PRNewswire/ - The American Professional Society of ADHD and Related Disorders (APSARD) is a U.S.-based international...

Tris Pharma to Present Two Posters for Amphetamine Extended-Release Tablet at the 2019

November 07, 2019

MONMOUTH JUNCTION, NJ, November 7, 2019 / PRNewswire/ - Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved...

Tris Pharma Adds Seasoned Attorney to its Senior Leadership Team

October 30, 2019

FOR IMMEDIATE RELEASE - MONMOUTH JUNCTION, NJ, October 30, 2019 / PRNewswire/ - Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust...

Tris Pharma Strengthens Its Branded Commercial Leadership Team

September 04, 2019

Todd Killian to lead Market Access and Trade Relations Scott Brunetto to lead Commercial Operations and Analytics MONMOUTH JUNCTION, NJ,...

Tris Pharma Chief Medical Officer Elected to the American Psychiatric Association Assembly Executive Committee

August 14, 2019

FOR INFORMATION Cheryl Patnick (732) 823-4940 cpatnick@trispharma.com MONMOUTH JUNCTION, NJ, August 14, 2019 / PRNewswire/ - Tris Pharma,...

Tris Pharma, Inc Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen

January 29, 2019

FOR IMMEDIATE RELEASE – January 29, 2019 – Monmouth Junction, NJ, Tris Pharma, Inc. is expanding the scope of its November 2018 recall by adding three (3)...

Information Related to the Voluntary Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL

January 28, 2019

Tris Pharma recently issued an expansion of the voluntary recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL and an...

Tris Pharma to Present Three Posters Covering Data on Dyanavel® XR and Tris’ LiquiXR® Technology at the 2019 APSARD Annual Meeting

January 17, 2019

MONMOUTH JUNCTION, NJ, January 17, 2019 / PRNewswire/ - Tris Pharma, Inc. (Tris), a biopharmaceutical company focused on developing innovative products that...

Information Related to the Voluntary Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL

December 06, 2018

Tris Pharma recently issued a voluntary recall and an associated press release regarding 3 batches (00717009A, 00717015A, 00717024A) of Infant’s Ibuprofen...

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

December 05, 2018

MONMOUTH JUNCTION, NJ, December 05, 2018 / PRNewswire/ -– Monmouth Junction, NJ, Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’...

Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine) at the 2018 Neuroscience Education Institute (NEI) Congress

November 12, 2018

The trial of children 6 to 12 years with ADHD demonstrated that DYANAVEL XR was effective in reducing symptoms of ADHD at 4 hours with a clinical onset at 1...

Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra® XR

November 05, 2018

ENGLEWOOD, CO / ACCESSWIRE / November 5, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization...

Tris Pharma Presents Results from Two Clinical Studies on Dyanavel® XR at the Largest Annual Meeting of Child and Adolescent Psychiatrists

October 25, 2018

MONMOUTH JUNCTION, NJ, October 24, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a biopharmaceutical company focused on developing innovative products that...

Tris Pharma Announces Hiring of Chief Commercial Officer

October 10, 2018

MONMOUTH JUNCTION, NJ, October 10, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative...

Deerfield Provides $125 million Debt Financing to Tris Pharma

October 04, 2018

Deerfield provides growth capital financing to Tris Pharma New York, New York – October 4, 2018 – Deerfield announced today it provided $125 million to...

Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals

September 25, 2018

MONMOUTH JUNCTION, NJ, September 25, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative...

Tris Pharma Announces Hiring of New Vice President of Quality & Compliance

August 27, 2018

MONMOUTH JUNCTION, NJ, August 27, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative technology-based...

Tris Pharma’s Results from a Laboratory Classroom Study of DYANAVEL® XR in Children with ADHD Featured at APSARD

February 09, 2017

MONMOUTH JUNCTION, N.J., February 9, 2017 - Tris Pharma, Inc. (“Tris”) announced that results from a laboratory classroom study of DYANAVEL XR...

FDA accepts CCP-08 NDA for full review

December 20, 2016

Vernalis plc and Tris Pharma, Inc. (“Tris”) are pleased to announce that the U.S. Food and Drug Administration (“FDA”) has accepted the CCP-08 New...

FDA Accepts CCP-07 NDA for Full Review

September 05, 2016

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-07 New Drug...

Tris Pharma Announces the Launch of DYANAVEL™ XR (amphetamine) Extended-release Oral Suspension, CII for the Treatment of Children with ADHD

April 19, 2016

MONMOUTH JUNCTION, N.J., April 19, 2016 - Tris Pharma, Inc. ("Tris") announces today the launch of DYANAVEL™ XR (amphetamine), CII, the...

Tris Pharma Announces First Ever FDA-Approved Extended-Release Chewable Tablet

December 16, 2015

MONMOUTH JUNCTION, NJ, December 16, 2015 / PRNewswire/ - Tris Pharma, Inc. ("Tris") is pleased to announce that the U.S. Food and Drug Administration ("FDA")...

Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII

December 07, 2015

NEW YORK, N.Y., December 7 -- Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer...

Tris Pharma Receives FDA Approval of Dyanavel™ XR (amphetamine) CII as Once-Daily Liquid for Treatment of ADHD in Children

October 20, 2015

MONMOUTH JUNCTION, N.J., October 20, 2015 -- Tris Pharma, Inc. ("Tris") announced that the U.S. Food and Drug Administration ("FDA") has approved...

Tris Pharma Launches Generic Tussionex® as Par’s Rights Expire

October 01, 2015

Monmouth Junction, N.J., Oct. 1, 2015 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery...

Vernalis PLC launches Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex) for cough relief with 12-hour dosing

September 07, 2015

Vernalis plc (LSE: VER) and Tris Pharma today announce that Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral...

FSC Pediatrics Launches Karbinal™ ER (carbinoxamine maleate) For the Symptomatic Treatment of Seasonal and Perennial Allergic Rhinitis for Children

August 13, 2015

CHARLOTTE, N.C., August 13, 2015; - FSC Pediatrics announced today the launch of Karbinal™ ER, the only 1st generation extended-release oral...

Tris Pharma and Pfizer Consumer Healthcare Enter Into Agreement to Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup under the Robitussin® Brand

June 29, 2015

MONMOUTH JUNCTION, N.J., June 29, 2015; - Tris Pharma, Inc. ("Tris") today announced that it has entered into a license, supply, and distribution agreement...

Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel™ XR

May 21, 2015

MONMOUTH JUNCTION, N.J., May 21, 2015; - Tris Pharma, Inc. ("Tris") announced that U.S. Food and Drug Administration ("FDA") has accepted for review its...

Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR

May 01, 2015

MONMOUTH JUNCTION, N.J., May 1, 2015; - Vernalis plc and Tris Pharma Inc. today announce that the U.S. Food and Drug Administration (FDA) has approved the...

FDA accepts Tuzistra™ XR (CCP-01) NDA for full review

September 15, 2014

MONMOUTH JUNCTION, N.J., September 15, 2014; - Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug...

Tris Pharma Receives NJBIA Award for Excellence

August 27, 2014

MONMOUTH JUNCTION, N.J., August 27, 2014; - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,...

Third Product in Vernalis’ Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept

July 22, 2014

Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their...

Submission of Tuzistra™ XR (CCP-01) NDA to FDA

June 30, 2014

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that a New Drug Application ("NDA") has been submitted to the U.S. Food and Drug...

Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept

April 01, 2014

Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-07, the second programme to achieve this milestone in...

Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01

February 01, 2014

Vernalis plc today announces successful completion of the second and final CCP-01 pivotal comparative bioavailability study. This positive multi-dose study...

Tris Pharma and FSC Laboratories Sign Definitive Commercialization dafabet live casinoAgreement for Karbinal™ ER (carbinoxamine maleate) Extended-Release Oral Suspension

September 04, 2013

MONMOUTH JUNCTION, N.J. & CHARLOTTE, N.C., September 4, 2013 -- Tris Pharma, Inc. and FSC Laboratories, Inc. today announced the signing of a definitive...

Tris Pharma’s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution

July 10, 2013

MONMOUTH JUNCTION, N.J., July 10, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

Tris Pharma Hires President for Generic Pharmaceuticals Business

June 20, 2013

MONMOUTH JUNCTION, N.J., June 20, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

Tris Pharma’s Ketan Mehta Among Ernst & Young Entrepreneur Of The Year® 2013 Finalists in New Jersey

May 02, 2013

MONMOUTH JUNCTION, N.J., May 2, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

FDA Approves Tris Pharma’s New Drug Application for KarbinalTM ER (carbinoxamine maleate) Extended-release Oral Suspension

April 03, 2013

MONMOUTH JUNCTION, N.J., April 3, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...

First Product in Tris Pharma’s Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris

March 11, 2013

MONMOUTH JUNCTION, N.J., March 11, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,...

Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States

January 14, 2013

NEW YORK, N.Y., January 14 - Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral...

Pfizer To Acquire NextWave Pharmaceuticals, Inc.

October 22, 2012

NEW YORK--(BUSINESS WIRE[1])--Pfizer Inc [2]. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals [3], a privately held, specialty...

Perrigo and Tris Pharma launch store brand version of Delsym®

August 27, 2012

ALLEGAN, Mich. and MONMOUTH JUNCTION, NJ – August 27, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) and Tris Pharma, Inc. today announced the commercial...

Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals

July 11, 2012

MONMOUTH JUNCTION, N.J., July 11; /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug...

Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension

May 31, 2012

MONMOUTH JUNCTION, N.J., May 31; /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company announced today that the US Food and Drug...

Perrigo announces FDA final approval of Tris Pharma’s Dextromethorphan Polistirex extended-release oral Suspension

May 30, 2012

ALLEGAN, Mich. – May 30, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) today announced that the U.S. Food and Drug Administration has granted final approval...

Vernalis and Tris Pharma announce collaboration to develop and commercialize novel products for the US prescription cough/cold market

February 06, 2012

Vernalis plc (Vernalis), a UK development stage pharmaceutical company listed on the London Stock Exchange (LSE:VER) and Tris Pharma Inc (Tris) a privately...

Tris Pharma Announces US Patent Grant Covering Platform Technology

January 06, 2012

MONMOUTH JUNCTION, N.J., January 6; /PRNewswire/ -- Tris Pharma, an emerging specialty pharmaceutical company announced the US grant of its core technology...

Contact us

Interested in learning more about our products, pipeline, and partnerships?

Required fields are indicated with "*".